Login to Your Account

Medivation Wins Big Again; Gets $110M Up Front in Astellas Deal

By Jennifer Boggs

Wednesday, October 28, 2009
When Medivation Inc. gained clearance in March to start its Phase III trial of MDV3100 in prostate cancer, a company executive told BioWorld Today the firm would consider partnering the drug if the right opportunity came along - as it had for Alzheimer's disease drug Dimebon, which scored a potential $725 million deal with Pfizer Inc. last year. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription